ArticleBMC cancer2023

Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors.

Jiani Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.